NFKB1 and pancreatic neoplasm: Since GSK-3 inhibition efficiently suppresses NF-κB in pancreatic cancer cells, and downregulates NF-κB targets associated with chemotherapy resistance such as XIAP and Bcl-XL, it seemed reasonable to predict that this would also sensitize these cells to gemcitabine.